Polymer nanotherapeutics with the controlled release of
acetylsalicylic acid and its derivatives inhibiting
cyclooxygenase isoforms and reducing the production of
pro-inflammatory mediators

J 2024

Polymer nanotherapeutics with the controlled release of acetylsalicylic acid and its derivatives inhibiting cyclooxygenase isoforms and reducing the production of pro-inflammatory mediators

FREJKOVÁ, Markéta; Kateřina BĚHALOVÁ; Daniela RUBANOVÁ; Juan Bautista DE SANCTIS; Lukáš KUBALA et al.

Základní údaje

Originální název

Polymer nanotherapeutics with the controlled release of acetylsalicylic acid and its derivatives inhibiting cyclooxygenase isoforms and reducing the production of pro-inflammatory mediators

Autoři

Vydání

International Journal of Pharmaceutics, Elsevier B.V. 2024, 0378-5173

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.200

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/24:00137936

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

Drug delivery; HPMA; Nanotherapeutics; Inflammation; Acetylsalicylic acid; Salicylic acid hydrazide

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 12. 2024 10:53, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

The effective treatment of inflammatory diseases, particularly their chronic forms, is a key task of modern medicine. Herein, we report the synthesis and evaluation of biocompatible polymer conjugates based on N-2(hydroxypropyl)methacrylamide copolymers enabling the controlled release of acetylsalicylic acid (ASA)-based anti-inflammatory drugs under specific stimuli. All polymer nanotherapeutics were proposed as water-soluble drug delivery systems with a hydrodynamic size below 10 nm ensuring suitability for the parenteral application and preventing opsonization by the reticuloendothelial system. The nanotherapeutics bearing an esterbound ASA exhibited long-term release of the ASA/salicylic acid mixture, while the nanotherapeutics carrying salicylic acid hydrazide (SAH) ensured the selective release of SAH in the acidic inflammatory environment thanks to the pH-sensitive hydrazone bond between the polymer carrier and SAH. The ASA- and SAH-containing nanotherapeutics inhibited both cyclooxygenase isoforms and/or the production of pro-inflammatory mediators. Thanks to their favorable design, they can preferentially accumulate in the inflamed tissue, resulting in reduced side effects and lower dosage, and thus more effective and safer treatment.

Citovat

FREJKOVÁ, Markéta; Kateřina BĚHALOVÁ; Daniela RUBANOVÁ; Juan Bautista DE SANCTIS; Lukáš KUBALA; Petr CHYTIL; Alice ŠIMONOVÁ; Tomáš KŘÍŽEK; Eva RANDÁROVÁ; Kristýna GUNÁR a Tomáš ETRYCH. Polymer nanotherapeutics with the controlled release of acetylsalicylic acid and its derivatives inhibiting cyclooxygenase isoforms and reducing the production of pro-inflammatory mediators. International Journal of Pharmaceutics. Elsevier B.V., 2024, roč. 665, November, s. 124742-124754. ISSN 0378-5173. Dostupné z: https://doi.org/10.1016/j.ijpharm.2024.124742.

@article{2459099,
   author = {Frejková, Markéta and Běhalová, Kateřina and Rubanová, Daniela and De Sanctis, Juan Bautista and Kubala, Lukáš and Chytil, Petr and Šimonová, Alice and Křížek, Tomáš and Randárová, Eva and Gunár, Kristýna and Etrych, Tomáš},
   article_number = {November},
   doi = {https://doi.org/10.1016/j.ijpharm.2024.124742},
   keywords = {Drug delivery; HPMA; Nanotherapeutics; Inflammation; Acetylsalicylic acid; Salicylic acid hydrazide},
   language = {eng},
   issn = {0378-5173},
   journal = {International Journal of Pharmaceutics},
   title = {Polymer nanotherapeutics with the controlled release of acetylsalicylic acid and its derivatives inhibiting cyclooxygenase isoforms and reducing the production of pro-inflammatory mediators},
   url = {https://www.sciencedirect.com/science/article/pii/S0378517324009761},
   volume = {665},
   year = {2024}
}

TY  - JOUR
ID  - 2459099
AU  - Frejková, Markéta - Běhalová, Kateřina - Rubanová, Daniela - De Sanctis, Juan Bautista - Kubala, Lukáš - Chytil, Petr - Šimonová, Alice - Křížek, Tomáš - Randárová, Eva - Gunár, Kristýna - Etrych, Tomáš
PY  - 2024
TI  - Polymer nanotherapeutics with the controlled release of acetylsalicylic acid and its derivatives inhibiting cyclooxygenase isoforms and reducing the production of pro-inflammatory mediators
JF  - International Journal of Pharmaceutics
VL  - 665
IS  - November
SP  - 124742
EP  - 124742
PB  - Elsevier B.V.
SN  - 03785173
KW  - Drug delivery
KW  - HPMA
KW  - Nanotherapeutics
KW  - Inflammation
KW  - Acetylsalicylic acid
KW  - Salicylic acid hydrazide
UR  - https://www.sciencedirect.com/science/article/pii/S0378517324009761
N2  - The effective treatment of inflammatory diseases, particularly their chronic forms, is a key task of modern medicine. Herein, we report the synthesis and evaluation of biocompatible polymer conjugates based on N-2(hydroxypropyl)methacrylamide copolymers enabling the controlled release of acetylsalicylic acid (ASA)-based anti-inflammatory drugs under specific stimuli. All polymer nanotherapeutics were proposed as water-soluble drug delivery systems with a hydrodynamic size below 10 nm ensuring suitability for the parenteral application and preventing opsonization by the reticuloendothelial system. The nanotherapeutics bearing an esterbound ASA exhibited long-term release of the ASA/salicylic acid mixture, while the nanotherapeutics carrying salicylic acid hydrazide (SAH) ensured the selective release of SAH in the acidic inflammatory environment thanks to the pH-sensitive hydrazone bond between the polymer carrier and SAH. The ASA- and SAH-containing nanotherapeutics inhibited both cyclooxygenase isoforms and/or the production of pro-inflammatory mediators. Thanks to their favorable design, they can preferentially accumulate in the inflamed tissue, resulting in reduced side effects and lower dosage, and thus more effective and safer treatment.
ER  -

FREJKOVÁ, Markéta; Kateřina BĚHALOVÁ; Daniela RUBANOVÁ; Juan Bautista DE SANCTIS; Lukáš KUBALA; Petr CHYTIL; Alice ŠIMONOVÁ; Tomáš KŘÍŽEK; Eva RANDÁROVÁ; Kristýna GUNÁR a Tomáš ETRYCH. Polymer nanotherapeutics with the controlled release of acetylsalicylic acid and its derivatives inhibiting cyclooxygenase isoforms and reducing the production of pro-inflammatory mediators. \textit{International Journal of Pharmaceutics}. Elsevier B.V., 2024, roč.~665, November, s.~124742-124754. ISSN~0378-5173. Dostupné z: https://doi.org/10.1016/j.ijpharm.2024.124742.

Přehled o publikaci